Arvid Söderhäll, Empros Pharma CEO
March 5, 2024 06:52 AM ESTUpdated 08:31 AM
R&D

Swedish biotech un­veils topline da­ta on weight loss drug de­signed for main­te­nance af­ter GLP-1s

Katherine Lewin

News Reporter

Em­pros Phar­ma’s oral weight loss drug on­ly de­liv­ered an av­er­age 8% body weight re­duc­tion in its Phase IIb test. So it can’t bat­tle with big …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times